Ampio pharmaceuticals to present at the 14th international congress on systemic lupus erythematosus (lupus 2021) & 6th international congress on controversies in rheumatology and autoimmunity (cora)

Englewood, colo., july 28, 2021 /prnewswire/ --  ampio pharmaceuticals  (nyse american: ampe), a biopharmaceutical company focused on the advancement of immunology-based therapies for prevalent inflammatory conditions, today announced details on the company's abstract presentation, "significant inhibition of the tlr7/cxcl10 signaling axis by lmwf5a in monocytic lineages; implications for covid-19 and lupus nephritis," being given virtually at the 14th international congress on systemic lupus erythematosus (lupus 2021) & 6th international congress on controversies in rheumatology and autoimmunity (cora) on october 6-9, 2021.
AMPE Ratings Summary
AMPE Quant Ranking